By using molecular markers (e.g., IDH, ATRX, 1p19q) and histological characteristics like cellular heterogeneity, nuclear polymorphisms, vascular proliferation and intratumoral necrosis, gliomas can be classified in grade I to IV, reflecting the clinical outcome of the patients [7]. This evidence concerns the gene IDH2 and central nervous system cancer.